Core Viewpoint - The successful implementation of the Y90 glass microsphere system at Jinan University First Affiliated Hospital marks a significant advancement in the treatment of primary liver cancer in the Guangdong-Hong Kong-Macao Greater Bay Area, showcasing the potential for innovative, minimally invasive therapies to improve patient outcomes [1][5]. Summary by Sections Patient Background and Treatment Decision - A patient with primary liver cancer, previously experiencing dizziness, headaches, and high blood pressure, was evaluated by a multidisciplinary team. Traditional surgical options were deemed high-risk for recurrence, leading to the recommendation of Y90 glass microsphere therapy for better long-term outcomes [2][3]. Clinical Context of Liver Cancer in China - China bears the highest burden of liver cancer globally, accounting for 42.4% of cases. Over 367,700 new cases are reported annually, with 70%-80% of patients unable to undergo direct surgical resection at initial treatment. The five-year survival rate for domestic liver cancer patients is only 14.1% [3]. Y90 Glass Microsphere Technology - The Y90 glass microsphere is the first radioactive tumor treatment device approved in the Greater Bay Area and the first globally to receive FDA approval for primary liver cancer treatment. It combines targeted radiation therapy with minimally invasive techniques, allowing for personalized treatment plans [5][9]. Surgical Procedure and Benefits - The procedure utilized advanced imaging and intervention techniques, allowing for the injection of millions of Y90 microspheres directly into the tumor's blood supply. This method minimizes damage to surrounding healthy tissue and reduces side effects compared to traditional therapies [8]. Safety and Efficacy - The Y90 microspheres have a short half-life, releasing most of their radiation within two weeks and ceasing after 28 days. This minimizes long-term radiation exposure risks, enabling patients to return to normal life quickly post-treatment [8]. Future Prospects - Jinan University First Affiliated Hospital plans to establish a Y90 center in 2024, aiming to integrate multidisciplinary advantages and provide cutting-edge treatment options for liver cancer patients in the Greater Bay Area and nationwide [8]. Clinical Outcomes - Internationally, Y90 glass microspheres have been used for over 20 years, treating more than 200,000 cases. Studies indicate that patients receiving this treatment can achieve significant tumor reduction, with a median survival of 12.5 years and a three-year survival rate of 93% for those who subsequently undergo liver transplantation or surgical resection [9].